Search Results - "Kohnen, Daniel"

Co-evolution of tumor and immune cells during progression of multiple myeloma by Liu, Ruiyang, Gao, Qingsong, Foltz, Steven M., Fowles, Jared S., Yao, Lijun, Wang, Julia Tianjiao, Cao, Song, Sun, Hua, Wendl, Michael C., Sethuraman, Sunantha, Weerasinghe, Amila, Rettig, Michael P., Storrs, Erik P., Yoon, Christopher J., Wyczalkowski, Matthew A., McMichael, Joshua F., Kohnen, Daniel R., King, Justin, Goldsmith, Scott R., O’Neal, Julie, Fulton, Robert S., Fronick, Catrina C., Ley, Timothy J., Jayasinghe, Reyka G., Fiala, Mark A., Oh, Stephen T., DiPersio, John F., Vij, Ravi, Ding, Li

“…Multiple myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells. Despite recent treatment advances, it is still incurable as disease…”
Get full text

Evolution and structure of clinically relevant gene fusions in multiple myeloma by Foltz, Steven M., Gao, Qingsong, Yoon, Christopher J., Sun, Hua, Yao, Lijun, Li, Yize, Jayasinghe, Reyka G., Cao, Song, King, Justin, Kohnen, Daniel R., Fiala, Mark A., Ding, Li, Vij, Ravi

“…Multiple myeloma is a plasma cell blood cancer with frequent chromosomal translocations leading to gene fusions. To determine the clinical relevance of fusion…”
Get full text

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma by Federico, Cinzia, Alhallak, Kinan, Sun, Jennifer, Duncan, Kathleen, Azab, Feda, Sudlow, Gail P., de la Puente, Pilar, Muz, Barbara, Kapoor, Vaishali, Zhang, Luna, Yuan, Fangzheng, Markovic, Matea, Kotsybar, Joseph, Wasden, Katherine, Guenthner, Nicole, Gurley, Shannon, King, Justin, Kohnen, Daniel, Salama, Noha N., Thotala, Dinesh, Hallahan, Dennis E., Vij, Ravi, DiPersio, John F., Achilefu, Samuel, Azab, Abdel Kareem

“…Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major…”
Get full text

The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant by Manjappa, Shivaprasad, Fiala, Mark A., King, Justin, Kohnen, Daniel A., Vij, Ravi

Get full text

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma by Barnell, Erica K., Skidmore, Zachary L., Newcomer, Kenneth F., Chavez, Monique, Campbell, Katie M., Cotto, Kelsy C., Spies, Nicholas C., Ruzinova, Marianna B., Wang, Tianjiao, Abro, Brooj, Kreisel, Friederike, Parikh, Bijal A., Duncavage, Eric J., Frater, John L., Lee, Yi-Shan, Hassan, Anjum, King, Justin A., Kohnen, Daniel R., Fiala, Mark A., Welch, John S., Uy, Geoffrey L., Vij, Kiran, Vij, Ravi, Griffith, Malachi, Griffith, Obi L., Wartman, Lukas D.

“…•B-ALL development in the setting of lenalidomide treatment for MM is a distinct primary malignancy with high incidence of TP53 mutations.•Chronic lenalidomide…”
Get full text

15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma by Yao, Lijun, Wang, Julia T., Jayasinghe, Reyka G., O'Neal, Julie, Tsai, Chia-Feng, Rettig, Michael P., Song, Yizhe, Liu, Ruiyang, Zhao, Yanyan, Ibrahim, Omar M., Fiala, Mark A., Fortier, Julie M., Chen, Siqi, Gehrs, Leah, Martins Rodrigues, Fernanda, Wendl, Michael C., Kohnen, Daniel, Shinkle, Andrew, Cao, Song, Foltz, Steven M., Cui Zhou, Daniel, Storrs, Erik, Wyczalkowski, Matthew A., Mani, Smrithi, Goldsmith, Scott R., Zhu, Ying, Hamilton, Mark, Liu, Tao, Chen, Feng, Vij, Ravi, Ding, Li, DiPersio, John F.

Get full text

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy by Alhallak, Kinan, Sun, Jennifer, Wasden, Katherine, Guenthner, Nicole, O’Neal, Julie, Muz, Barbara, King, Justin, Kohnen, Daniel, Vij, Ravi, Achilefu, Samuel, DiPersio, John F., Azab, Abdel Kareem

“…T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs), has shown promising clinical outcomes in many cancers; however, these…”
Get full text

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma by Sun, Jennifer, Muz, Barbara, Alhallak, Kinan, Markovic, Matea, Gurley, Shannon, Wang, Zhe, Guenthner, Nicole, Wasden, Katherine, Fiala, Mark, King, Justin, Kohnen, Daniel, Salama, Noha Nabil, Vij, Ravi, Azab, Abdel Kareem

“…Multiple myeloma (MM) remains to be incurable despite recent therapeutic advances. CD47, an immune checkpoint known as the "don't eat me" signal, is highly…”
Get full text

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma by de la Puente, Pilar, Luderer, Micah J., Federico, Cinzia, Jin, Abbey, Gilson, Rebecca C., Egbulefu, Christopher, Alhallak, Kinan, Shah, Shruti, Muz, Barbara, Sun, Jennifer, King, Justin, Kohnen, Daniel, Salama, Noha Nabil, Achilefu, Samuel, Vij, Ravi, Azab, Abdel Kareem

“…The establishment of more effective treatments that can circumvent chemoresistance in Multiple Myeloma (MM) is a priority. Although bortezomib (BTZ) is one of…”
Get full text

Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma by Muz, Barbara, Wasden, Katherine, Alhallak, Kinan, Jeske, Amanda, Azab, Feda, Sun, Jennifer, King, Justin, Kohnen, Daniel R., Vij, Ravi, Azab, Abdel Kareem

“…Introduction: Multiple myeloma (MM) is a lymphoplasmacytic malignancy localized in the bone marrow (BM) characterized by the continuous metastasis. Despite the…”
Get full text

Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma by Yao, Lijun, Wang, Julia T, Jayasinghe, Reyka G, O'Neal, Julie, Tsai, Chia-Feng, Rettig, Michael P, Song, Yizhe, Liu, Ruiyang, Zhao, Yanyan, Ibrahim, Omar M, Fiala, Mark A, Fortier, Julie M, Chen, Siqi, Gehrs, Leah, Rodrigues, Fernanda Martins, Wendl, Michael C, Kohnen, Daniel, Shinkle, Andrew, Cao, Song, Foltz, Steven M, Zhou, Daniel Cui, Storrs, Erik, Wyczalkowski, Matthew A, Mani, Smrithi, Goldsmith, Scott R, Zhu, Ying, Hamilton, Mark, Liu, Tao, Chen, Feng, Vij, Ravi, Ding, Li, DiPersio, John F

“…Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of…”
Get full text

3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients by Jeske, Amanda, Azab, Feda, De La Puente, Pilar, Muz, Barbara, King, Justin, Kohnen, Daniel R., Vij, Ravi, Azab, Abdel Kareem

“…Background: Multiple Myeloma (MM) is the second most common hematological malignancy, and continues to be a fatal disease even with the development of novel…”
Get full text

Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium by Federico, Cinzia, Muz, Barbara, Sun, Jennifer, Alhallak, Kinan, King, Justin, Kohnen, Daniel R., Fiala, Mark A., Roccaro, Aldo M., Vij, Ravi, Azab, Abdel Kareem

“…Proteasome inhibitors (PIs) have improved the treatment of multiple myeloma (MM) and prolonged patient survival, but several challenges remain to overcome…”
Get full text

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages by Wang, Tianjiao, Sun, Hua, Cui Zhou, Daniel, Liu, Ruiyang, Yao, Lijun, Fiala, Mark A., Kohnen, Daniel R., O'Neal, Julie, Rettig, Michael P., Fowles, Jared S, Oh, Stephen T., Jayasinghe, Reyka G, Vij, Ravi, DiPersio, John F., Ding, Li

“…Multiple myeloma (MM) is a hematological malignancy, defined by aberrant monoclonal proliferation of plasma cells in the bone marrow, that to date remains an…”
Get full text

Inhibition of CD47 as a Novel Cancer Immunotherapy for Multiple Myeloma by Sun, Jennifer, Muz, Barbara, Alhallak, Kinan, King, Justin, Kohnen, Daniel, Fiala, Mark, Vij, Ravi, Azab, Kareem

Get full text

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood by Muz, Barbara, De La Puente, Pilar, King, Justin A, Kohnen, Daniel R, Vij, Ravi, Azab, Abdel Kareem

“…Introduction: The presence of a minimal residual disease (MRD) that remains after treatment is one of the main reasons for recurrence and relapse in multiple…”
Get full text

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant by King, Justin A, Fiala, Mark A, Kohnen, Daniel R, Wildes, Tanya M, Stockerl-Goldstein, Keith, Vij, Ravi

“…Background: For patients relapsing after initial autologous stem cell transplantation (ASCT), a second ASCT is a potential, although infrequently used, salvage…”
Get full text

Targeting CD47 As a Novel Therapeutic Strategy in Multiple Myeloma by Muz, Barbara, Kusdono, Hubert D, King, Justin, Kohnen, Daniel, Fiala, Mark A., Vij, Ravi, Capoccia, Ben, Manning, Pamela T., Salama, Noha Nabil, Azab, Abdel Kareem

“…Introduction: CD47 is an immune checkpoint coordinating the innate and adaptive immune systems which allows cancer cells to escape the innate immune response…”
Get full text

Characterization of Germline Variants in Multiple Myeloma by Martins Rodrigues, Fernanda, Gao, Qingsong, Huang, Kuan-lin, Scott, Adam David, Foltz, Steven M., King, Justin, Fiala, Mark A., Kohnen, Daniel R., DiPersio, John F., Vij, Ravi, Ding, Li

“…Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow. Like…”
Get full text

Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort by Foltz, Steven M., Gao, Qingsong, Yoon, Christopher J., Weerasinghe, Amila, Sun, Hua, Yao, Lijun, Fiala, Mark A., Kohnen, Daniel R., King, Justin, Ju, Yeong Seok, DiPersio, John F., Vij, Ravi, Ding, Li

“…Introduction: Gene fusions are the result of genomic rearrangements that create hybrid protein products or bring the regulatory elements of one gene into close…”
Get full text